Mevacor Daily OTC Switch Rejected Based On Patient Inability To Self Select
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA joint committee finds that current system does not ensure appropriate patient self-selection for cholesterol-lowering therapy. Committee votes 20-3 against OTC marketing for Mevacor Daily. Behind-the-counter strategy for pharmacy urged.
You may also be interested in...
J&J/Merck's Mevacor OTC Switch Appears To Be "Not Approvable" At FDA
Merck's receipt of a letter from FDA on the eve of the Feb. 24 user fee deadline, coupled with statements from the agency, suggest that FDA deemed the statin "not approvable" for OTC sale. Advisory committees voted against the switch in January.
J&J/Merck's Mevacor OTC Switch Appears To Be "Not Approvable" At FDA
Merck's receipt of a letter from FDA on the eve of the Feb. 24 user fee deadline, coupled with statements from the agency, suggest that FDA deemed the statin "not approvable" for OTC sale. Advisory committees voted against the switch in January.
FDAers Sink Mevacor OTC At Panel Meeting With Unflinching Critique
Presentations by FDA OTC division cast Johnson & Johnson/Merck Mevacor OTC studies in negative light during advisory committee meeting. FDAers cite low rates of proper self-selection, comprehension for CUSTOM actual-use study.